Baxter sells its Vero cell technology; Santen, Durect form drug delivery partnership;

> Baxter International ($BAX) entered into a definitive agreement to sell its Vero cell-based technology for vaccine production to Nanotherapeutics. Release

> Santen Pharmaceutical now has exclusive worldwide rights to sell a sustained-release product that uses Durect's saber technology. The terms of an agreement between the two companies calls for Santen to pay Durect a fee of $2 million. Story

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.